Vivotif Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The vivotif market research report is one of a series of new reports that provides vivotif market statistics, including vivotif industry global market size, regional shares, competitors with a vivotif market share, detailed vivotif market segments, market trends and opportunities, and any further data you may need to thrive in the vivotif industry. This vivotif market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing awareness about benefits of vaccination, increasing incidence of typhoid fever, convenience and effectiveness of oral vaccines, advancements of vaccine technology, and increase in research activities. Major trends in the forecast period include growing preference for oral vaccines, increased focus on travel vaccines, integration of vivotif into travel health kits, development of combination vaccines, and shift towards preventive healthcare.

The growing incidence of typhoid fever is expected to drive the expansion of the vivotif market in the future. Typhoid fever, caused by the Salmonella Typhi bacteria, spreads through contaminated food or water and leads to symptoms such as fever, abdominal pain, and fatigue. The rise in typhoid fever cases can be linked to factors such as inadequate sanitation, limited access to clean water, and increasing antibiotic resistance, especially in low-income areas. Vivotif, an oral vaccine, helps reduce the occurrence of typhoid fever by providing prevention against Salmonella Typhi, particularly in regions with poor sanitation. For example, in August 2024, reports from GOV.UK indicated that 645 cases of typhoid fever were reported in England, Wales, and Northern Ireland in 2023, up from 470 cases in 2022, highlighting an increase in the disease's incidence. Consequently, the rising rates of typhoid fever are driving demand for vivotif.

The growth of the vivotif market is also supported by an increase in healthcare spending. Healthcare spending encompasses the total investment in health services, including medical care, hospital services, medications, preventive care, infrastructure, research, and administrative costs, all aimed at improving the health and well-being of populations. The rise in healthcare expenditure is driven by factors such as an aging population, advances in medical technology, the increasing prevalence of chronic diseases, and the growing demand for healthcare services. The boost in healthcare funding supports Vivotif by facilitating the research, production, and distribution of the oral typhoid vaccine, ensuring it reaches populations at risk of typhoid fever. This allocation of resources contributes to public health efforts, especially in areas where the disease is most prevalent. For instance, the Office for National Statistics reported a 5.6% increase in UK healthcare spending from 2022 to 2023, with total expenditure reaching approximately $317.63 billion (£292 billion). Thus, the growth in healthcare spending is helping to drive the vivotif market.

In May 2023, Bavarian Nordic A/S, a pharmaceutical company based in Denmark, acquired Emergent BioSolutions for $0.274 billion. This acquisition allows Bavarian Nordic to enhance its vaccine portfolio by adding Vivotif, a vaccine for typhoid fever, along with Vaxchora for cholera and a Phase 3 Chikungunya vaccine. Emergent BioSolutions, a US-based life sciences company, develops Vivotif, and this strategic move strengthens Bavarian Nordic's position in the global vaccine market.

The key company operating in the vivotif market is Bavarian Nordic A/S.

Asia-Pacific was the largest region in the vivotif market in 2024. The regions covered in vivotif report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vivotif market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Vivotif is an oral vaccine designed to prevent typhoid fever, a potentially life-threatening illness caused by the bacterium Salmonella typhi. It is approved for use in adults and children over 6 years of age and is recommended for individuals at higher risk, such as travelers to endemic areas, those with close exposure to S. typhi carriers, and microbiology laboratorians frequently working with S. typhi.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main clinical indication for vivotif is the prevention of typhoid fever, although it may be used for other related indications. Typhoid is a bacterial infection primarily caused by Salmonella Typhi, which spreads through contaminated food or water. Vivotif is distributed through various channels, including direct sales, online pharmacies, and retail pharmacies, and is used by a wide range of end-users, including both adults and pediatric populations.

The vivotif market consists of sales of oral typhoid vaccines and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.